On Thursday morning, Rockwell Medical (RMTI) announced positive top-line results from CRUISE-1, the first of two Phase 3 trials for SFP, which is simply a salt form of iron that can be added to dialysate to maintain chronic kidney disease (CKD) patients' hemoglobin. Iron deficiency anemia is an ongoing concern for dialysis patients, and SFP has the potential to become the market leader in iron replacement. Not long ago, I wrote an article arguing that due to pending catalysts and the advancement of their business model, the short thesis for Rockwell Medical had played out. The successful release of CRUISE-1 data confirms one of the planks of my argument, and these positive results bode well for CRUISE...
Rockwell Medical CRUISE Data Is Positive - Implications For The Next Move
Jul 12 2013, 03:45 | about: RMTI
BOOKMARKED / READ LATER
Added to your bookmarks on the Seeking Alpha homepage